The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.76
Bid: 5.22
Ask: 6.50
Change: 0.10 (1.74%)
Spread: 1.28 (24.521%)
Open: 5.76
High: 5.76
Low: 5.76
Prev. Close: 5.76
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: SulNOx raises funds; Synairgen shares trial results

Fri, 23rd Dec 2022 17:05

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

SulNOx Group PLC - London-based green technology company - Raises around GBP760,000 via placing and subscription of new shares at 11.5 pence price. Says largest shareholder Nistad AS invests further GBP80,000 to hold 13% in equity at SulNox. Follows announcement from yesterday which proposed fundraise to raise a minimum of GBP750,0000. "Despite difficult market conditions, we are pleased to have received institutional investor backing for SulNOx as an ESG, energy transition company with tremendous potential from reducing fossil fuel consumption and emissions across the globe," says Chief Executive Officer Ben Richardson. "Following the fundraising, SulNOx will have a runway to deliver increasing revenues and be able to accelerate our growth plans through 2023."

----------

Cindrigo Holdings Ltd - London-based clean energy producer - Reaches agreement with Danir AB, its largest shareholder and creditor, to provide new funding and restructure short-term debt of GBP4.3 million into long-term convertible loans. Danir provides additional loan funding of GBP750,000, following BK Fortuna AS's reported failure to provide agreed funding to Cindrigo, as announced on September 30. Says additional Danir funding is via 24-month convertible loan with a 5% interest rate per year. Says this loan is convertible into Cindrigo shares from 60 days after the company is readmitted to listing, with conversion price equal to the higher of either a 25% discount to the 30-day volume-weighted average share price or the minimum price per share of 125 pence. Existing GBP3.8m debt funding from Danir will be restructured and replaced by issue of new 10-year zero coupon convertible loan notes with a conversion price of 15p per share. Can be converted for a maximum of 25.3 million new Cindrigo shares.

----------

Synairgen PLC - Southampton, England-based respiratory company developing SNG001 treatment, containing the broad-spectrum antiviral protein interferon beta - Publishes results of Sprinter phase 3 trial in the European Respiratory Journal Open Research. Says while Sprinter trial does not meet the primary endpoints of discharge from the hospital and recovery, there is an encouraging signal in reduction in the relative risk of progression to severe disease or death with 35 days. Says SNG001 is well tolerated, as shown in previous clinical trials. Chief Scientific Officer & Lead Author Phillip Monk says: "The results from the SG016 phase 2 and the Sprinter trial of SNG001 in hospitalised patients, and the Activ-2 trial in the home setting, suggest that SNG001 may be preventing progression to severe disease. With these data, we remain confident in the potential of SNG001 as a broad-spectrum antiviral for high-risk patient populations infected with respiratory viruses including influenza and RSV and are focused on its continued clinical development." Says SNG001 is not approved for use anywhere in the world.

----------

Wentworth Resources PLC - Tanzania-focused natural gas production company - Says it expects to achieve an average gross daily production rate of around 90 million standard cubic feet per day for 2022, compared to previous guidance of between 75MMscf/d and 85MMscf/d. As of Monday, current production levels are steady at a supply-constrained 90MMscf/d, below current demand nominations of 95MMscf/d from its key offtaker the Tanzania Petroleum Development Corp. Says Mnazi Bay joint venture is undertaking an infield workover and perforation programme, aiming to meet gas demand nominations in 2023. Hopes production levels will reach 90MMscf/d from late 2024 until at least 2027. Cash is USD30.0 million on December 1, while joint venture capital expenditure budget for 2023 is USD13.5 million.

----------

SEEEN PLC - London-based media and technology platform - Raises around GBP2.6 million via open offer of 523,887 shares. Says net proceeds are intended to bolster company's sales and marketing team, alongside investing into technology development projects to support planned next stage of growth.

----------

Dolphin Capital Investors Ltd - Cardiff, Wales-based investor in high-end resort developments in the eastern Mediterranean - Completes the EUR17.9 million disposal of its entire interest in the One&Only at Kea Island project. Prior to sale, Dolphin was 67% owner of Single Purpose Vehicle Ten Ltd, which owned 50% of OOKI, giving Dolphin Capital an effective 33% equity interest in OOKI. Receives EUR900,000 of sale proceeds on December 5 as an advance payment. Receives the remaining EUR17.0 million balance on completion. Around EUR13.0 million of the disposal proceeds used to repay its existing loan facility by December 31, which Dolphin Capital drew down in June and July. Says all debt has now been fully repaid.

----------

Curtis Banks Group PLC - Bristol-based financial services company - Says Nucleus Financial Platforms Ltd completes its due diligence amid advanced discussions over a possible offer for the entire share capital of Curtis Banks. Says both parties are close to agreeing transaction. Extends deadline for nucleus to announce offer to January 9 from Friday. Follows announcement of a potential takeover on November 25.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
5 Sep 2022 18:25

TRADING UPDATES: Bradda wins drilling approval; Oakley invests in vLex

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
5 Sep 2022 10:42

Synairgen to collaborate with University of Southampton on observational study

(Sharecast News) - Drug discovery outfit Synairgen will collaborate with the University of Southampton on an observational study aimed at exploring and better understanding acute respiratory viral infections and recovery.

Read more
23 Jun 2022 16:02

UK shareholder meetings calendar - next 7 days

Friday 24 June 
AFC Energy PLCGM re fees for non-executive directors
Avast PLCAGM
Devolver Digital IncAGM
Entain PLCAGM
Gulf Keystone Petroleum LtdAGM
Hawkwing PLCAGM
Invesco Bond Income Plus LtdAGM
Life Science REITAGM
Northcoders Group PLCAGM
Princess Private Equity Holding LtdAGM
Monday 27 June 
Anglo-Eastern Plantations PLCAGM
Celadon Pharmaceuticals PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Echo Energy PLCAGM
Medica Group PLCAGM
Pelatro PLCAGM
Surgical Innovations Group PLCAGM
Warpaint London PLCAGM
Tuesday 28 June 
4D Pharma PLCAGM
Acceler8 Ventures PLCAGM
Airtel Africa PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Attraqt Group PLCAGM
Bay Capital PLCAGM
Capital & Counties Properties PLCAGM
CMO Group PLCAGM
Corre Energy BVAGM
Creo Medical Group PLCAGM
Futura Medical PLCAGM
Gama Aviation PLCAGM
ICG Enterprise Trust PLCAGM
ImmuPharma PLCAGM
IQE PLCAGM
Katoro Gold PLCAGM
Rockhopper Exploration PLCAGM
Sound Energy PLCAGM
TP Group PLCAGM
UK Oil & Gas PLCAGM
Volvere PLCAGM
Zegona Communications PLCAGM
Wednesday 29 June 
Africa Opportunity Fund LtdAGM
Argo Blockchain PLCAGM
Atome Energy PLCAGM
Brave Bison Group PLCAGM
Concurrent Technologies PLCAGM
Eden Research PLCAGM
Facilities by ADF PLCAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
HeiQ PLCAGM
Helios Underwriting PLCAGM
Hurricane Energy PLCAGM
i(x) Net Zero PLCAGM
Lords Group Trading PLCAGM
MaxCyte IncAGM
Meggitt PLCAGM
Mobile Tornado Group PLCAGM
NB Distressed Debt Investment Fund LtdAGM
NetScientific PLCAGM
Provident Financial PLCAGM
RA International Group PLCAGM
Reabold Resources PLCAGM
Symphony Environmental Technologies PLCAGM
Team17 Group PLCAGM
ThinkSmart LtdGM re approval for capital return
Trinity Exploration & Production PLCAGM
URA Holdings PLCAGM
XP Factory PLCAGM
Zaim Credit Systems PLCAGM
Thursday 30 June 
3i Group PLCAGM
Ashtead Technology Holdings PLCAGM
Borders & Southern Petroleum PLCAGM
Caspian Sunrise PLCAGM
Cobra Resources PLCAGM
Crimson Tide PLCAGM
ECSC Group PLCAGM
Evraz PLCAGM
Gresham House Energy Storage Fund PLCAGM
GRIT Investment Trust PLCAGM
Gulf Marine Services PLCAGM
Hamak Gold LtdAGM
Hemogenyx Pharmaceuticals PLCAGM
Immotion Group PLCAGM
Inspiration Healthcare Group PLCAGM
Inspired PLCAGM
Jadestone Energy PLCAGM
Kanabo Group PLCAGM
Kropz PLCAGM
Likewise Group PLCAGM
Live Co Group PLCAGM
Location Sciences Group PLCAGM
LoopUp Group PLCAGM
M&C Saatchi PLCAGM
Microsaic Systems PLCAGM
Nostra Terra Oil & Gas CoAGM
Pathfinder Minerals PLCAGM
Playtech PLCAGM
Primorus Investments PLCAGM
Rockfire Resources PLCAGM
Roquefort Therapeutics PLCAGM
Sanne Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serica Energy PLCAGM
Supply@ME Capital PLCAGM
Surface Transforms PLCAGM
Synairgen PLCAGM
Tower Resources PLCAGM
Trainline PLCAGM
ValiRx PLCAGM
Victoria Oil & Gas PLCAGM
Watchstone Group PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
25 May 2022 12:00

IN BRIEF: Synairgen shares fall as loss widens on higher costs

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Records a pretax loss of GBP57.9 million in 2021, widened from GBP17.7 million in 2020, as research and development costs jump to GBP52.9 million from GBP15.5 million. Further, administrative expenses more than double to GBP5.0 million from GBP2.2 million. Explains this with its phase 3 Sprinter trial that started patient recruitment in January 2021. The trial is for SNG001, an inhaled drug for the treatment of Covid-19. Says the remainder of the research and development expenditure was used for upscaling SNG001 manufacturing development activities and procuring long lead time components.

Read more
16 May 2022 15:23

Synairgen posts positive clinical trial data for SNG001

(Sharecast News) - Shares of Synairgen caught a bid following the release of clinical trial results which appeared to show that its SNG001 formulation against Covid-19 might lower the risk of severe disease or death in the most at risk patients.

Read more
16 May 2022 12:18

LONDON MARKET MIDDAY: FTSE 100 edges into green but grey clouds remain

(Alliance News) - The FTSE 100 index put a toe into positive territory by midday on Monday, reclaiming all the ground lost earlier in the morning, but investors continue to fret about poor economic data from China.

Read more
16 May 2022 12:18

IN BRIEF: Synairgen shares soar on positive analysis of SNG001

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Notes that it announced in February that its phase 3 Sprinter trial did not meet its primary endpoints of discharge from hospital and recovery. Says that the trial still showed an encouraging signal in the reduction in the relative risk of progression to severe disease or death within 35 days. Says that it performed a post hoc analysis on groups of patients recognised to be at greater risk of developing severe disease in hospital, to assess the strength of this signal. Says that the analyses showed stronger treatment effects with SNG001 in high-risk patient sub-groups, with the strongest effect observed in those who had clinical signs of compromised respiratory function. Says SNG001 significantly reduced the risk of progression to severe disease and death compared to a placebo by 70% in the per-protocol population.

Read more
17 Mar 2022 12:32

Synairgen falls as patient recruitment halted on Covid-19 trial

(Sharecast News) - Inhaled antiviral treatment developer Synairgen said on Thursday that the US National Institute of Allergy and Infectious Diseases (NIAID) has halted all patient recruitment in its phase 2 and 3 Covid-19 trial, which included the assessment of its 'SNG001' treatment.

Read more
17 Mar 2022 11:48

IN BRIEF: Synairgen falls as patient recruitment in US trial halted

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Says the US National Institute of Allergy & Infectious Diseases has halted all patient recruitment in its phase 2/3 Covid-19 trial. The trial included the assessment of its inhaled SNG001 drug.

Read more
17 Mar 2022 11:21

AIM WINNERS & LOSERS: Synairgen sinks 18% after US Covid study halted

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
3 Mar 2022 20:34

TRADING UPDATES: Next Fifteen raises GBP50 million; N Brown sales up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
3 Mar 2022 12:20

Synairgen asked to pause activities on Covid-19 treatment trial

(Sharecast News) - Synairgen announced on Thursday that it was pausing clinical trial activities on its 'SNG001' compound in the treatment of Covid-19, at the behest of American authorities.

Read more
3 Mar 2022 11:29

AIM WINNERS & LOSERS: dotDigital plunges after profit warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
21 Feb 2022 12:25

Synairgen falls as trial for Covid treatment fails to meet endpoints

(Alliance News) - Synairgen PLC shares hit a 12-month low on Monday after the biotechnology company said that the late-stage trial of its Covid-19 treatment SNG001 did not meet primary or key secondary efficacy endpoints.

Read more
21 Feb 2022 11:33

AIM WINNERS & LOSERS: Morses Club sinks on profit warning, CEO exit

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.